155 related articles for article (PubMed ID: 18037104)
1. Treatment of idiopathic membranous nephropathy with the herb Astragalus membranaceus.
Ahmed MS; Hou SH; Battaglia MC; Picken MM; Leehey DJ
Am J Kidney Dis; 2007 Dec; 50(6):1028-32. PubMed ID: 18037104
[TBL] [Abstract][Full Text] [Related]
2. Idiopathic membranous nephropathy: diagnosis and treatment.
Fervenza FC; Sethi S; Specks U
Clin J Am Soc Nephrol; 2008 May; 3(3):905-19. PubMed ID: 18235148
[TBL] [Abstract][Full Text] [Related]
3. [Treatment of idiopathic membranous nephropathy. Is the anti-CD20 antibody rituximab a reasonable option?].
Busch M; Gerth J; Ott U; Schip A; Haufe CC; Gröne HJ; Wolf G
Med Klin (Munich); 2008 Jul; 103(7):519-24. PubMed ID: 18604487
[TBL] [Abstract][Full Text] [Related]
4. Remission of membranous nephropathy after therapy with Astragalus membranaceus.
Leehey DJ; Casini T; Massey D
Am J Kidney Dis; 2010 Apr; 55(4):772. PubMed ID: 20338467
[No Abstract] [Full Text] [Related]
5. Corticosteroids and ciclosporin A in idiopathic membranous nephropathy: higher remission rates of nephrotic syndrome and less adverse reactions than after traditional treatment with cytotoxic drugs.
Goumenos DS; Katopodis KP; Passadakis P; Vardaki E; Liakopoulos V; Dafnis E; Stefanidis I; Vargemezis V; Vlachojannis JG; Siamopoulos KC
Am J Nephrol; 2007; 27(3):226-31. PubMed ID: 17389782
[TBL] [Abstract][Full Text] [Related]
6. Cyclosporin A treatment for idiopathic membranous nephropathy.
Yao X; Chen H; Wang Q; Tang Z; Hu W; Yin G; Liu Z; Li L
Chin Med J (Engl); 2001 Dec; 114(12):1305-8. PubMed ID: 11793859
[TBL] [Abstract][Full Text] [Related]
7. Long-term outcome of patients with membranous nephropathy after complete remission of proteinuria.
Passerini P; Pasquali S; Cesana B; Zucchelli P; Ponticelli C
Nephrol Dial Transplant; 1989; 4(6):525-9. PubMed ID: 2507973
[TBL] [Abstract][Full Text] [Related]
8. ACTH and azathioprine: antiproteinuric and lipid-lowering effect in the course of idiopathic membranous glomerulonephritis.
Gigante A; Rosato E; Liberatori M; Gasperini ML; Giannakakis K; Barbano B; Cianci R; Salsano F; Amoroso A
J Biol Regul Homeost Agents; 2012; 26(1):135-8. PubMed ID: 22475105
[TBL] [Abstract][Full Text] [Related]
9. Astragaloside IV attenuates complement membranous attack complex induced podocyte injury through the MAPK pathway.
Zheng R; Deng Y; Chen Y; Fan J; Zhang M; Zhong Y; Zhu R; Wang L
Phytother Res; 2012 Jun; 26(6):892-8. PubMed ID: 22086717
[TBL] [Abstract][Full Text] [Related]
10. Astragalus membranaceus reduces free radical-mediated injury to renal tubules in rabbits receiving high-energy shock waves.
Sheng BW; Chen XF; Zhao J; He DL; Nan XY
Chin Med J (Engl); 2005 Jan; 118(1):43-9. PubMed ID: 15642225
[TBL] [Abstract][Full Text] [Related]
11. Effectiveness of steroid therapy in different stages of membranous nephropathy.
Fuiano G; Stanziale P; Balletta M; Sepe V; Marinelli G; Comi N; Esposito A; Andreucci VE
Nephrol Dial Transplant; 1989; 4(12):1022-9. PubMed ID: 2517322
[TBL] [Abstract][Full Text] [Related]
12. Prednisolone and azathioprine in membranous nephropathy: a 10-year follow-up study.
Goumenos DS; Ahuja M; Davlouros P; El Nahas AM; Brown CB
Clin Nephrol; 2006 May; 65(5):317-23. PubMed ID: 16724651
[TBL] [Abstract][Full Text] [Related]
13. [Idiopathic membranous nephropathy associated with anti-calcineurin toxicity. Prognosis and other immunosuppressive treatments].
Muñoz Díaz AB; Aguilar P
Nefrologia; 2004; 24 Suppl 3():76-80. PubMed ID: 15219075
[TBL] [Abstract][Full Text] [Related]
14. Pharmacologic management of adult idiopathic nephrotic syndrome.
Alaniz C; Brosius FC; Palmieri J
Clin Pharm; 1993 Jun; 12(6):429-39. PubMed ID: 8403814
[TBL] [Abstract][Full Text] [Related]
15. Low-dose angiotensin-converting-enzyme inhibitor captopril to reduce proteinuria in adult idiopathic membranous nephropathy: a prospective study of long-term treatment.
Rostoker G; Ben Maadi A; Remy P; Lang P; Lagrue G; Weil B
Nephrol Dial Transplant; 1995; 10(1):25-9. PubMed ID: 7724024
[TBL] [Abstract][Full Text] [Related]
16. Antioxidant treatment of therapy-resistant idiopathic membranous nephropathy with probucol: a pilot study.
Haas M; Mayer G; Wirnsberger G; Holzer H; Ratschek M; Neyer U; Neuweiler J; Kramar R; Schneider B; Breiteneder-Geleff S; Regele HM; Hörl WH; Kerjaschki D
Wien Klin Wochenschr; 2002 Feb; 114(4):143-7. PubMed ID: 12060980
[TBL] [Abstract][Full Text] [Related]
17. Meta-analysis of the clinical value of Astragalus membranaceus in diabetic nephropathy.
Li M; Wang W; Xue J; Gu Y; Lin S
J Ethnopharmacol; 2011 Jan; 133(2):412-9. PubMed ID: 20951192
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of low-dose chlorambucil in nephrotic patients with idiopathic membranous nephropathy.
Idasiak-Piechocka I; Oko A; Łochyńska-Bielecka K; Skrobańska B
Kidney Blood Press Res; 2009; 32(4):263-7. PubMed ID: 19776643
[TBL] [Abstract][Full Text] [Related]
19. Idiopathic membranous nephropathy: outline and rationale of a treatment strategy.
du Buf-Vereijken PW; Branten AJ; Wetzels JF
Am J Kidney Dis; 2005 Dec; 46(6):1012-29. PubMed ID: 16310567
[TBL] [Abstract][Full Text] [Related]
20. A randomized pilot trial comparing methylprednisolone plus a cytotoxic agent versus synthetic adrenocorticotropic hormone in idiopathic membranous nephropathy.
Ponticelli C; Passerini P; Salvadori M; Manno C; Viola BF; Pasquali S; Mandolfo S; Messa P
Am J Kidney Dis; 2006 Feb; 47(2):233-40. PubMed ID: 16431252
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
